NCM
XBI icon

Nantahala Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nantahala Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,646
Closed -$2.1M – 149
2024
Q3 		$2.14M Sell
21,646
-723
-3% -$71K 0.11% 97
2024
Q2 		$2.07M Sell
22,369
-19,700
-47% -$1.77M 0.12% 90
2024
Q1 		$3.99M Buy
+42,069
New +$3.9M 0.23% 74

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nantahala Capital Management's XBI Position: Q4 2024 in Review

Nantahala Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 21,646 shares — an estimated $2.1M sold.

Nantahala Capital Management first reported a position in XBI in Q1 2024 and held it in 3 quarters. The position peaked at $3.99M in Q1 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Nantahala Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 21,646 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $2.1M.
  • Nantahala Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 3 quarters.
  • Nantahala Capital Management's State Street SPDR S&P Biotech ETF position peaked at $3.99M in Q1 2024.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.